The Guangdong-Hong Kong-Macao Greater Bay Area (GBA) has emerged as a dazzling pearl in China's biomedical industry, thanks to its remarkable economic openness and vitality. With strong support from national and local policies, this region has swiftly become a hub for biomedical enterprises, demonstrating vigorous development momentum. Predictions indicate that by 2028, the GDP of the GBA's health industry will exceed RMB 2 trillion, further growing to a range of RMB 2.5 trillion to RMB 3 trillion by 2030.

From September 9th to 11th, the highly anticipated CPHI & PMEC Pharmaceutical Industry Exhibition was held grandly at the Shenzhen Convention and Exhibition Center (Futian). This exhibition focused on the Asian market and centered around new drug development and process technology innovation, meticulously crafting a professional and technology-oriented industry promotion platform.

As a leader in the API field, PRIME MOLECULAR participated throughout the event, embarking on a fulfilling and rewarding exhibition journey.

At the exhibition site, the PRIME MOLECULAR team quickly immersed themselves in the vibrant industry atmosphere. Pharmaceutical enterprises from around the globe gathered to showcase their innovative achievements and cutting-edge technologies. With anticipation and enthusiasm, we navigated through various exhibition areas, diligently studied the displays of each exhibitor, engaged in in-depth exchanges and discussions with domestic and international peers, explored cooperation opportunities, and jointly mapped out a development blueprint.

Through this exhibition, we gained a comprehensive understanding of the latest industry dynamics and development trends, absorbed valuable experiences and insights from peers, and conducted in-depth discussions with numerous buyers on cooperation opportunities. Centering on core topics such as new drug development, process optimization, technology barrier breakthroughs, precise market positioning, and marketing strategy innovation, we engaged in detailed and fruitful exchanges with multiple pharmaceutical enterprises. This exchange not only significantly broadened our horizons but also accumulated abundant resources for the company's future development.

Visiting the CPHI & PMEC Pharmaceutical Industry Exhibition (Shenzhen), we returned with a wealth of gains. This was not only a precious opportunity to closely encounter the forefront practices of the pharmaceutical industry but also an excellent platform for expanding industry connections and deepening cooperation.

Looking ahead, PRIME MOLECULAR will fully leverage the opportunity presented by this exhibition to continuously enhance its research and development capabilities and innovation prowess, delving deeper into the API field, and providing medical customers with higher-quality and more cost-effective product options. Meanwhile, we will actively support Chinese pharmaceutical enterprises in expanding into the GBA and Asian markets, achieving broader development prospects.

Through this grand event, we look forward to contributing even more prominently to the sustained and healthy development of the pharmaceutical industry in China and globally. For clients who expressed interest in cooperation at the exhibition, PRIME MOLECULAR has already initiated follow-up communications and sincerely invites other interested partners to contact us at any time for mutual development and shared brilliance.